US 2020/0046822 A1 · METHOD FOR PRODUCING Hib CONJUGATE VACCINE USING PRP WITH LOWERED MOLECULAR WEIGHT

Abstract

A method for preparing a PRP conjugate having high storage stability and a method for producing a Hib conjugate vaccine are provided. A method for preparing PRP conjugate in accordance with the embodiments of the present invention is characterized by that the release of PRPs after preparing the PRP conjugate is suppressed by using PRP with a lowered molecular weight than native PRP for a coupling reaction between PRP and a carrier protein. Also, a Hib conjugate vaccine comprising as an antigen the PRP conjugate prepared by said method has excellent storage stability and maintain sufficient immunogenicity.

Claims15

Dependent claims

A method for preparing a polyribosylribitol phosphate (PRP) conjugate via a coupling reaction of PRP and a carrier protein wherein the method is characterized by that the release of PRPs after preparing the PRP conjugate is suppressed by using PRP with a lowered molecular weight than native PRP.

Dependencies are inferred from the claim text.

Facts

Application

16/340,778Filed 11 Oct 2017

Priority

JP 2016-20603320 Oct 2016

Published

13 Feb 2020

Term ends

Not estimatedThe source records don’t support an estimate.

Classification10 codes

A61K 39/102
Bacterial antigens: pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
A61K 39/08
Bacterial antigens: clostridium, e.g. Clostridium tetani
A61K 39/385
Medicinal preparations containing antigens or antibodies: haptens or antigens, bound to carriers
A61P 31/04
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics: antibacterial agents

METHOD FOR PRODUCING Hib CONJUGATE VACCINE USING PRP WITH LOWERED MOLECULAR WEIGHT

Life of this patent

METHOD FOR PRODUCING Hib CONJUGATE VACCINE USING PRP WITH LOWERED MOLECULAR WEIGHT

Life of this patent

Abstract

Claims15